The winter baby killer has a nemesis! The first drug available for respiratory syncytial virus infection in infants on the domestic market
穿越夜时空簿
发表于 2024-1-3 17:23:38
1323
0
0
On January 2nd, AstraZeneca and Sanofi jointly developed a long-acting monoclonal antibody called Nirsevimab, which was officially approved for marketing by the National Medical Products Administration of China. It is used to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants. The drug is expected to be launched in China during the 2024-2025 RSV infection season.
Respiratory syncytial virus (RSV) is a common respiratory virus. Due to the fact that cells infected with the virus fuse together, forming a large cell structure similar to a "syncytial body", they are vividly referred to as respiratory "syncytial" viruses. RSV is more prevalent in winter and early spring, and the epidemic season in the Northern Hemisphere usually starts in October or November, and can last until April or May of the following year. The peak period usually occurs in January or February.
China is one of the countries with a high incidence of RSV worldwide. Research shows that from 2009 to 2019, influenza virus and RSV ranked among the top two pathogens detected in the total population of acute respiratory infections in China, with proportions of 28.5% and 16.8%, respectively.
Research has shown that over 60% of acute lower respiratory tract infections in young children and 80% of infections in infants under 1 year old are caused by RSV. According to data from the World Health Organization, syncytial virus infection is the leading cause of hospitalization or even death in children under the age of five due to virus infection, hence the nickname "winter baby killer".
The newly approved Nissevir monoclonal antibody is the first and only approved preventive measure in China to protect the general infant population against RSV infection, covering healthy full-term infants, premature infants, and infants who are susceptible to severe RSV infection due to special health conditions. The approval of niseverumab in China is mainly based on the results of three key clinical trials and clinical research and development projects in China. For all clinical trial endpoints, a single injection of niseverumab has shown consistent efficacy in treating lower respiratory tract diseases caused by respiratory syncytial virus, with a sustainable protection period of five months, which is a typical RSV infection season.
In response, Professor Liu Hanmin, Dean of West China Second Hospital of Sichuan University and Principal Investigator (PI) of Phase III Clinical Trials of Nisevirumab in China, said, "This approval for marketing in China not only reduces the disease burden caused by syncytial virus infection in children and families, but also hopes to reduce the burden on the medical system caused by respiratory diseases in pediatrics. This will contribute an important force to the prevention and control of syncytial virus in China."
It is worth noting that as early as March 2017, AstraZeneca and Sanofi announced a cooperation agreement for the development and commercialization of nisetizumab. According to the terms of the agreement, AstraZeneca is responsible for product development and production, while Sanofi is responsible for product commercialization and revenue measurement. The two companies share costs and profits in all regions except the United States. The revenue generated by AstraZeneca based on this agreement is classified as alliance revenue and partnership revenue in the company's financial statements.
AstraZeneca's General Manager in China, Lai Minglong, pointed out that Nisetumab has filled the gap in the prevention of respiratory syncytial virus in newborns and infants in China, and is of great significance for protecting the health of Chinese infants. We hope that this drug can provide an "immune umbrella" for newborns and infants during their first RSV infection season. In the future, AstraZeneca will also accelerate research and development innovation, further enriching its product pipeline.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The world's first! French regulatory authorities sue NVIDIA
- Alibaba launches the first AI picture book tool in China to care for children with autism
- JD Group and Hailan Group have reached a strategic cooperation and will open the first JD Aolai offline store
- Modner claims that the company has reached a joint agreement with Mitsubishi Tanabe Pharmaceuticals to promote the company's mRNA respiratory vaccine portfolio in Japan
- NIO's first fourth substitution power station in Beijing officially goes online
- New breakthrough in AI chips! SK Hynix, the world's first to achieve mass production of 12 layer HBM3E products, saw its stock price surge by nearly 9%
- The first new force in car manufacturing! Ideal car's one millionth complete vehicle rolled off the production line
- Mingchuang Youpin Ye Guofu: Retail industry should not compromise on prices. Going abroad should first go to Southeast Asia and then to Europe and America
- Is OpenAI's first AI assistant product for the 'next major breakthrough' or will it be released in January next year to revolutionize human-computer interaction?
- Xiaopeng Motors opens its first store in Australia
-
生成式人工知能(AI)が巻き起こす技術の波の中で、電力会社は意外にも資本市場の寵児になった。 今年のスタンダード500割株の上昇幅ランキングでは、Vistraなどの従来の電力会社が注目を集め、株価が2倍になってリ ...
- xifangczy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
グーグルは現地時間12月19日、新しい「推理」モデルとしてGemini 2.0 Flash Thinkingを発売すると発表した。紹介によると、このモデルはまだ実験段階であり、訓練を経た後、モデルが反応を起こした時に経験した「思 ...
- 地下水
- 3 天前
- 支持
- 反对
- 回复
- 收藏